PCV (13-valent, adsorbed): patient group direction (PGD) template

PGD template to support the national pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV) vaccination programme.


PCV (13-valent, adsorbed): patient group direction (PGD) template

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This patient group direction (PGD) template is to support the administration of pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV13) to individuals from 6 weeks (routinely from 8 weeks) to under 2 years of age in accordance with the national immunisation programme.

It is valid from 1 February 2019 to 31 January 2021.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 4 February 2016
Last updated 15 January 2019 + show all updates
  1. Added updated PGD template: validity from 6 weeks of age and addition of outbreak indication.
  2. Added notice of extension for PCV (13-valent, adsorbed) patient group direction.
  3. First published.